ProQR Therapeutics (PRQR) Raised to “Hold” at Zacks Investment Research
Zacks Investment Research upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a sell rating to a hold rating in a report released on Wednesday.
According to Zacks, “ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company’s lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands. “
A number of other brokerages also recently weighed in on PRQR. Evercore ISI assumed coverage on ProQR Therapeutics in a research note on Tuesday, September 18th. They issued an outperform rating and a $35.00 price objective on the stock. BidaskClub raised ProQR Therapeutics from a buy rating to a strong-buy rating in a research note on Wednesday, October 24th. ValuEngine raised ProQR Therapeutics from a buy rating to a strong-buy rating in a research note on Thursday, September 6th. HC Wainwright reissued a buy rating and issued a $20.00 price objective on shares of ProQR Therapeutics in a research note on Tuesday, October 30th. Finally, Chardan Capital reissued a buy rating and issued a $9.00 price objective on shares of ProQR Therapeutics in a research note on Monday, August 13th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $18.00.
ProQR Therapeutics (NASDAQ:PRQR) last issued its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.31) by $0.10. Analysts anticipate that ProQR Therapeutics will post -1.38 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of PRQR. JPMorgan Chase & Co. increased its position in ProQR Therapeutics by 519.0% in the 1st quarter. JPMorgan Chase & Co. now owns 33,425 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 28,025 shares during the period. Franklin Street Advisors Inc. NC increased its position in ProQR Therapeutics by 50.0% in the 2nd quarter. Franklin Street Advisors Inc. NC now owns 90,000 shares of the biopharmaceutical company’s stock worth $657,000 after buying an additional 30,000 shares during the period. Essex Investment Management Co. LLC bought a new position in ProQR Therapeutics in the 2nd quarter worth approximately $604,000. Jennison Associates LLC increased its position in ProQR Therapeutics by 1.0% in the 2nd quarter. Jennison Associates LLC now owns 2,981,205 shares of the biopharmaceutical company’s stock worth $21,763,000 after buying an additional 30,831 shares during the period. Finally, Ardsley Advisory Partners bought a new position in ProQR Therapeutics in the 2nd quarter worth approximately $365,000. 28.55% of the stock is currently owned by institutional investors.
ProQR Therapeutics Company Profile
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.